145 related articles for article (PubMed ID: 8105878)
1. Correlation of p53 expression and proliferative activity in gastric cancer.
Yonemura Y; Fushida S; Tsugawa K; Ninomiya I; Fonseca L; Yamaguchi A; Miyazaki I; Urano T; Shiku H
Anal Cell Pathol; 1993 Sep; 5(5):277-88. PubMed ID: 8105878
[TBL] [Abstract][Full Text] [Related]
2. Expression of p53 protein in gastric cancer: an immunohistochemical study with correlation to proliferative activity.
Ioachim E; Goussia A; Stefanou D; Agnantis NJ
Anticancer Res; 1997; 17(1A):513-7. PubMed ID: 9066704
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of p53 is associated with growth pattern and prognosis in advanced gastric cancer.
Ichiyoshi Y; Oiwa H; Tomisaki S; Sakaguchi Y; Ohno S; Maehara Y; Sugimachi K
Hepatogastroenterology; 1997; 44(14):546-53. PubMed ID: 9164535
[TBL] [Abstract][Full Text] [Related]
4. [Significance of COX-2, p53, proliferating cell nuclear antigen and nm23 expressions in gastric cancer and its behavior].
Ji SQ; Hua YW; Zhuang J; Gao Y; Kong Y; Han SL; Shao YF
Ai Zheng; 2002 Jun; 21(6):619-24. PubMed ID: 12452062
[TBL] [Abstract][Full Text] [Related]
5. [Correlation of DNA ploidy, c-erbB-2 protein tissue status, level of PCNA expression and clinical outcome in gastric carcinomas].
Takamura H; Yonemura Y; Hirono Y; Ninomiya I; Sahara H; Tsugawa K; Matsumoto H; Sugiyama K; Fujimura T; Nishimura G
Gan To Kagaku Ryoho; 1993 Apr; 20(6):788-95. PubMed ID: 8098198
[TBL] [Abstract][Full Text] [Related]
6. P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy.
Díez M; Medrano MJ; Gutierrez A; López A; Mugüerza JM; Hernández P; Lozano O; Noguerales F; Ruíz A; Granell J
Anticancer Res; 2000; 20(5C):3929-33. PubMed ID: 11268479
[TBL] [Abstract][Full Text] [Related]
7. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer.
Shun CT; Wu MS; Lin JT; Chen SY; Wang HP; Lee WJ; Wang TH; Chuang SM
Hepatogastroenterology; 1997; 44(14):604-9. PubMed ID: 9164544
[TBL] [Abstract][Full Text] [Related]
8. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
[TBL] [Abstract][Full Text] [Related]
9. Can p53 nuclear over-expression, Bcl-2 accumulation and PCNA status be of prognostic significance in high-risk superficial and invasive bladder tumours?
Plastiras D; Moutzouris G; Barbatis C; Presvelos V; Petrakos M; Theodorou C
Eur J Surg Oncol; 1999 Feb; 25(1):61-5. PubMed ID: 10188857
[TBL] [Abstract][Full Text] [Related]
10. p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy.
Lopes A; Bezerra AL; Pinto CA; Serrano SV; de MellO CA; Villa LL
J Urol; 2002 Jul; 168(1):81-6. PubMed ID: 12050497
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical staining for the p53 protein and proliferating cell nuclear antigen in familial clustering of gastric cancer.
Okusa Y; Ichikura T; Tamakuma S
J Surg Oncol; 1996 Aug; 62(4):253-7. PubMed ID: 8691838
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of p53 protein expression for patients with gastric cancer--a multivariate analysis.
Maehara Y; Tomoda M; Hasuda S; Kabashima A; Tokunaga E; Kakeji Y; Sugimachi K
Br J Cancer; 1999 Mar; 79(7-8):1255-61. PubMed ID: 10098768
[TBL] [Abstract][Full Text] [Related]
13. Mutated p53 protein expression and proliferative activity in advanced gastric cancer.
Ikeguchi M; Saito H; Kondo A; Tsujitani S; Maeta M; Kaibara N
Hepatogastroenterology; 1999; 46(28):2648-53. PubMed ID: 10522058
[TBL] [Abstract][Full Text] [Related]
14. p53 expression in non small cell lung cancer: clinical and biological correlations.
Fontanini G; Bigini D; Vignati S; Macchiarini P; Pepe S; Angeletti CA; Pingitore R; Squartini F
Anticancer Res; 1993; 13(3):737-42. PubMed ID: 8100413
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt.
el-A Helal T; Khalifa A; Kamel AS
Anticancer Res; 2000; 20(3B):2145-50. PubMed ID: 10928168
[TBL] [Abstract][Full Text] [Related]
16. Mutated p53 in tumors, mutant p53 and p53-specific antibodies in the circulation in patients with gastric cancer.
Maeta M; Saito H; Oka S; Tsujitani S; Ikeguchi M; Kaibara N
J Exp Clin Cancer Res; 2000 Dec; 19(4):489-95. PubMed ID: 11277328
[TBL] [Abstract][Full Text] [Related]
17. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade.
Wu CW; Lin YY; Chen GD; Chi CW; Carbone DP; Chen JY
Br J Cancer; 1999 May; 80(3-4):483-8. PubMed ID: 10408857
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of T antigen expression in patients with gastric carcinoma.
Chung YS; Yamashita Y; Kato Y; Nakata B; Sawada T; Sowa M
Cancer; 1996 May; 77(9):1768-73. PubMed ID: 8646672
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in early gastric cancer.
Kunisaki C; Shimada H; Takahashi M; Ookubo K; Moriwaki Y; Akiyama H; Nomura M
Hepatogastroenterology; 2001; 48(37):294-8. PubMed ID: 11268989
[TBL] [Abstract][Full Text] [Related]
20. Prognostic influence of p53 expression in gastric cancer.
Müller W; Borchard F
J Pathol; 1996 Mar; 178(3):255-8. PubMed ID: 8778328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
